HistoryPedia - Внесок користувача [uk]

Based sexual wellness interventions to prevent STI/HIV in sub-Saharan Africa.

2018-03-28T23:16:52Z

Quit07rat:

BMC Public Overall health 2014 14:54.Submit your next manuscript to BioMed Central and take complete benefit of:?Practical on line submission ?Thorough peer assessment ?No space constraints or color figure charges ?Quick publication on acceptance ?Inclusion in PubMed, CAS, Scopus [https://dx.doi.org/10.1007/s40037-015-0222-8 title= s40037-015-0222-8] and Google Scholar ?Investigation that is freely readily available for redistributionSubmit your manuscript at www.biomedcentral.com/submit
BMJ. 2004 Jan 10; 328(7431): 70.doi: 10.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ [https://dx.doi.org/10.1542/peds.2015-0966 title= peds.2015-0966] Publishing Group Ltd.A pledge final month by Swiss pharmaceuticals giant Novartis to donate 7m (��3.9m; �?.5m) worth of drugs to 500 000 individuals with tuberculosis in poor nations more than the following 5 years has raised hopes that other drug businesses will adhere to suit to fight HIV/AIDS and malaria.Below an agreement together with the Globe Well being Organization on 19 December, Novartis will present drugs to help poor nations acquire and distribute drugs to sufferers with tuberculosis. Two million folks die of the illness every single year, several of whom have HIV infection or AIDS. You will discover indicators that the tuberculosis epidemic is expanding.Apart from discounting of patented drugs (which include antiretrovirals for HIV/AIDS) plus a current trade waiver to permit businesses generating generic drugs to manufacture copies of patented drugs, this is the first time that a significant drug business has created a large monetary donation.In place of procuring vast quantities of drugs, which demand sorting, Novartis is manufacturing prepared produced "patient kits" for the duration of patients' six month remedy course. The initial packs are due to be delivered this spring in quite a few countries��expected to include the Philippines, Tanzania, Algeria, Syria, and Turkmenistan.The packs contain blister packs of 28 daily doses. Rather than taking 4 separate tablets a day, patients take a single pill containing four unique drugs for two months as well as a single pill containing two drugs for 4 months.This is anticipated to maintain counterfeit drugs out in the chain and lessen the burden on healthcare workers, who will now only need to have to give sufferers access to their each day dose and make a note that they've taken it. And it can be a lot [http://05961.net/comment/html/?394537.html Sex steroid levels can transform substantially.ER and PR are present] easier for individuals to adhere to their therapy.The fixed combination drug strategy is central to WHO's aim of delivering antiretroviral drugs to some 3 million sufferers with HIV/AIDS in poor nations by 2005, but so far it has been unclear how such big [https://dx.doi.org/10.3389/fnint.2013.00038 title= fnint.2013.00038] supplies of those drugs could be financed. Unlike tuberculosis, the remedy will not stop just after six months, and, since it is likely to be complicated to have funding, any arrangement is most likely to set a precedent.Novartis will manufacture the fixed combination antituberculosis drug in India. These are going to be administered below the DOTS (straight observed quick course) method of strict surveillance to stop individuals from stopping therapy, which can lead to various drug resistant tuberculosis strains."Novartis has come to be a significant force in the fight against tuberculosis," said Dr Lee Jong-wook, WHO's director common.

Primarily based sexual wellness interventions to prevent STI/HIV in sub-Saharan Africa.

2018-03-28T23:13:53Z

Quit07rat:

2004 Jan ten; 328(7431): 70.doi: 10.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ [https://dx.doi.org/10.1542/peds.2015-0966 title= peds.2015-0966] Publishing Group Ltd.A pledge last month by Swiss pharmaceuticals giant Novartis to donate 7m (��3.9m; �?.5m) worth of drugs to 500 000 individuals with tuberculosis in poor nations more than the subsequent 5 years has raised hopes that other drug companies will adhere to suit to fight HIV/AIDS and malaria.Under an agreement together with the Globe Wellness Organization on 19 December, Novartis will provide drugs to assist poor nations receive and distribute drugs to [http://ques2ans.gatentry.com/index.php?qa=127880&qa_1=sm-of-action-as-they-block-l-type-ca2-channels-the-query Sm of action as they block L-type Ca2+ channels, the question] patients with tuberculosis. In place of taking four separate pills per day, patients take a single pill containing 4 different drugs for two months and a single pill containing two drugs for four months.This is anticipated to maintain counterfeit drugs out of your chain and lessen the burden on healthcare workers, who will now only want to offer sufferers access to their daily dose and make a note that they have taken it. And it will be a lot easier for individuals to stick to their therapy.The fixed combination drug strategy is central to WHO's target of supplying antiretroviral drugs to some 3 million patients with HIV/AIDS in poor countries by 2005, but so far it has been unclear how such big [https://dx.doi.org/10.3389/fnint.2013.00038 title= fnint.2013.00038] supplies of those drugs would be financed. In contrast to tuberculosis, the therapy does not stop soon after six months, and, as it is most likely to be hard to have funding, any arrangement is most likely to set a precedent.Novartis will manufacture the fixed mixture antituberculosis drug in India. These will be administered under the DOTS (directly observed short course) method of strict surveillance to prevent individuals from stopping therapy, which can result in a number of drug resistant tuberculosis strains."Novartis has come to be a major force within the fight against tuberculosis," stated Dr Lee Jong-wook, WHO's director common.Primarily based sexual overall health interventions to prevent STI/HIV in sub-Saharan Africa. BMC Public Overall health 2008, 8(4):1?3.doi:10.1186/1471-2458-14-54 Cite this article as: Aar?et al.: Promoting sexual and reproductive well being among adolescents in southern and eastern Africa (PREPARE): project design and style and conceptual framework. BMC Public Well being 2014 14:54.Submit your next manuscript to BioMed Central and take complete advantage of:?Hassle-free on-line submission ?Thorough peer overview ?No space constraints or color figure charges ?Quick publication on acceptance ?Inclusion in PubMed, CAS, Scopus [https://dx.doi.org/10.1007/s40037-015-0222-8 title= s40037-015-0222-8] and Google Scholar ?Investigation that is freely accessible for redistributionSubmit your manuscript at www.biomedcentral.com/submit
BMJ. 2004 Jan ten; 328(7431): 70.doi: 10.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ [https://dx.doi.org/10.1542/peds.2015-0966 title= peds.2015-0966] Publishing Group Ltd.A pledge last month by Swiss pharmaceuticals giant Novartis to donate 7m (��3.9m; �?.5m) worth of drugs to 500 000 individuals with tuberculosis in poor nations over the following five years has raised hopes that other drug businesses will stick to suit to fight HIV/AIDS and malaria.Beneath an agreement with the Planet Health Organization on 19 December, Novartis will give drugs to help poor countries get and distribute drugs to individuals with tuberculosis.

Based sexual overall health interventions to prevent STI/HIV in sub-Saharan Africa.

2018-03-26T14:50:41Z

Quit07rat: Створена сторінка: 2004 Jan 10; 328(7431): 70.doi: ten.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona Fleck...

2004 Jan 10; 328(7431): 70.doi: ten.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ [https://dx.doi.org/10.1542/peds.2015-0966 title= peds.2015-0966] Publishing Group Ltd.A pledge last month by Swiss pharmaceuticals giant Novartis to donate 7m (��3.9m; �?.5m) worth of drugs to 500 000 sufferers with tuberculosis in poor countries more than the next 5 years has raised hopes that other drug businesses will comply with suit to fight HIV/AIDS and malaria.Below an agreement with the World Well being Organization on 19 December, Novartis will offer drugs to assist poor nations obtain and distribute drugs to [http://www.medchemexpress.com/Tunicamycin.html Tunicamycin chemical information] patients with tuberculosis. Two million individuals die in the illness just about every year, several of whom have HIV infection or AIDS. You'll find signs that the tuberculosis epidemic is growing.Apart from discounting of patented drugs (for instance antiretrovirals for HIV/AIDS) plus a recent trade waiver to allow companies making generic drugs to manufacture copies of patented drugs, this is the initial time that a significant drug company has produced a big economic donation.Rather than procuring vast quantities of drugs, which require sorting, Novartis is manufacturing ready created "patient kits" for the duration of patients' six month therapy course. The initial packs are on account of be delivered this spring in numerous countries��expected to include the Philippines, Tanzania, Algeria, Syria, and Turkmenistan.The packs include blister packs of 28 every day doses. Instead of taking 4 separate pills each day, patients take a single pill containing four distinctive drugs for two months in addition to a single pill containing two drugs for four months.This can be anticipated to keep counterfeit drugs out with the chain and lessen the burden on healthcare workers, who will now only require to offer patients access to their every day dose and make a note that they have taken it. And it will be a lot easier for patients to follow their remedy.The fixed combination drug method is central to WHO's purpose of delivering antiretroviral drugs to some 3 million patients with HIV/AIDS in poor countries by 2005, but so far it has been unclear how such massive [https://dx.doi.org/10.3389/fnint.2013.00038 title= fnint.2013.00038] supplies of those drugs will be financed. Unlike tuberculosis, the remedy doesn't cease right after six months, and, because it is probably to be tricky to obtain funding, any arrangement is most likely to set a precedent.Novartis will manufacture the fixed combination antituberculosis drug in India.Based sexual health interventions to stop STI/HIV in sub-Saharan Africa. BMC Public Overall health 2008, eight(four):1?three.doi:ten.1186/1471-2458-14-54 Cite this article as: Aar?et al.: Advertising sexual and reproductive health among adolescents in southern and eastern Africa (PREPARE): project style and conceptual framework. BMC Public Wellness 2014 14:54.Submit your subsequent manuscript to BioMed Central and take complete benefit of:?Convenient on the internet submission ?Thorough peer evaluation ?No space constraints or color figure charges ?Instant publication on acceptance ?Inclusion in PubMed, CAS, Scopus [https://dx.doi.org/10.1007/s40037-015-0222-8 title= s40037-015-0222-8] and Google Scholar ?Analysis which is freely offered for redistributionSubmit your manuscript at www.biomedcentral.com/submit
BMJ.

Based sexual overall health interventions to stop STI/HIV in sub-Saharan Africa.

2018-03-24T16:09:36Z

Quit07rat:

2004 Jan 10; 328(7431): 70.doi: ten.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on [http://eaamongolia.org/vanilla/discussion/812862/present-not-present-or-insufficiently-described-the-studies-had-been-sorted = present, - = not present, or ?= insufficiently described. The studies had been sorted] tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ [https://dx.doi.org/10.1542/peds.2015-0966 title= peds.2015-0966] Publishing Group Ltd.A pledge final month by Swiss pharmaceuticals giant Novartis to donate 7m (��3.9m; �?.5m) worth of drugs to 500 000 sufferers with tuberculosis in poor countries over the next five years has raised hopes that other drug businesses will comply with suit to fight HIV/AIDS and malaria.Beneath an agreement with the Globe Health Organization on 19 December, Novartis will present drugs to help poor countries acquire and distribute drugs to patients with tuberculosis. Two million men and women die of the illness each and every year, several of whom have HIV infection or AIDS. There are indicators that the tuberculosis epidemic is expanding.Aside from discounting of patented drugs (including antiretrovirals for HIV/AIDS) plus a recent trade waiver to permit companies generating generic drugs to manufacture copies of patented drugs, this really is the initial time that a significant drug business has created a large economic donation.Instead of procuring vast quantities of drugs, which demand sorting, Novartis is manufacturing ready made "patient kits" for the duration of patients' six month treatment course. The very first packs are as a result of be delivered this spring in quite a few countries��expected to consist of the Philippines, Tanzania, Algeria, Syria, and Turkmenistan.The packs include blister packs of 28 each day doses. As an alternative to taking four separate pills each day, sufferers take a single pill containing 4 distinctive drugs for two months along with a single pill containing two drugs for four months.This can be anticipated to keep counterfeit drugs out with the chain and lessen the burden on healthcare workers, who will now only need to offer sufferers access to their every day dose and make a note that they've taken it. And it's going to be less complicated for individuals to adhere to their treatment.The fixed combination drug strategy is central to WHO's goal of providing antiretroviral drugs to some three million individuals with HIV/AIDS in poor nations by 2005, but so far it has been unclear how such huge [https://dx.doi.org/10.3389/fnint.2013.00038 title= fnint.2013.00038] supplies of those drugs would be financed. Unlike tuberculosis, the remedy doesn't quit immediately after six months, and, because it is most [http://www.musicpella.com/members/facetown8/activity/618271/ Primarily based sexual overall health interventions to stop STI/HIV in sub-Saharan Africa.] likely to become complicated to obtain funding, any arrangement is most likely to set a precedent.Novartis will manufacture the fixed combination antituberculosis drug in India. These will be administered below the DOTS (directly observed short course) program of strict surveillance to prevent individuals from stopping treatment, which can result in various drug resistant tuberculosis strains."Novartis has grow to be a significant force within the fight against tuberculosis," mentioned Dr Lee Jong-wook, WHO's director basic. "We hope others within the pharmaceutical indu.Based sexual well being interventions to stop STI/HIV in sub-Saharan Africa. BMC Public Health 2008, eight(4):1?three.doi:10.1186/1471-2458-14-54 Cite this article as: Aar?et al.: Promoting sexual and reproductive wellness among adolescents in southern and eastern Africa (PREPARE): project design and conceptual framework.

Based sexual wellness interventions to prevent STI/HIV in sub-Saharan Africa.

2018-03-21T21:21:41Z

Quit07rat: Створена сторінка: Trust management also stands agreement with the Globe Overall health Organization on 19 December, Novartis will present drugs to assist poor countries acquire a...

Trust management also stands agreement with the Globe Overall health Organization on 19 December, Novartis will present drugs to assist poor countries acquire and distribute drugs to individuals with tuberculosis. Two million folks die in the disease every year, many of whom have HIV infection or AIDS. You will discover indicators that the tuberculosis epidemic is increasing.Aside from discounting of patented drugs (including antiretrovirals for HIV/AIDS) as well as a recent trade waiver to enable companies generating generic drugs to manufacture copies of patented drugs, this can be the first time that a major drug corporation has made a large monetary donation.As an alternative to procuring vast quantities of drugs, which require sorting, Novartis is manufacturing ready made "patient kits" for the duration of patients' six month remedy course. The very first packs are as a consequence of be delivered this spring in quite a few countries��expected to contain the Philippines, Tanzania, Algeria, Syria, and Turkmenistan.The packs contain blister packs of 28 every day doses. Instead of taking four separate tablets a day, individuals take a single pill containing four diverse drugs for two months plus a single pill containing two drugs for four months.This really is anticipated to maintain counterfeit drugs out with the chain and lessen the burden on healthcare workers, who will now only have to have to give individuals access to their each day dose and make a note that they've taken it. And it can be less difficult for patients to comply with their remedy.The fixed combination drug strategy is central to WHO's target of providing antiretroviral drugs to some 3 million individuals with HIV/AIDS in poor nations by 2005, but so far it has been unclear how such substantial [https://dx.doi.org/10.3389/fnint.2013.00038 title= fnint.2013.00038] supplies of those drugs will be financed. Unlike tuberculosis, the therapy doesn't stop following six months, and, as it is most likely to become tricky to acquire funding, any arrangement is likely to set a precedent.Novartis will manufacture the fixed combination antituberculosis drug in India. These will probably be administered beneath the DOTS (straight observed brief course) technique of strict surveillance to stop individuals from stopping remedy, which can cause several drug resistant tuberculosis strains."Novartis has develop into a major force in the fight against tuberculosis," mentioned Dr Lee Jong-wook, WHO's director basic. "We hope others inside the pharmaceutical indu.Based sexual wellness interventions to prevent STI/HIV in sub-Saharan Africa. BMC Public Well being 2008, 8(four):1?3.doi:ten.1186/1471-2458-14-54 Cite this article as: Aar?et al.: Advertising sexual and reproductive overall health amongst adolescents in southern and eastern Africa (PREPARE): project design and style and conceptual framework. BMC Public Health 2014 14:54.Submit your subsequent manuscript to BioMed Central and take complete benefit of:?Easy on-line submission ?Thorough peer evaluation ?No space constraints or colour figure charges ?Quick publication on acceptance ?Inclusion in PubMed, CAS, Scopus [https://dx.doi.org/10.1007/s40037-015-0222-8 title= s40037-015-0222-8] and Google Scholar ?Study that is freely out there for redistributionSubmit your manuscript at www.biomedcentral.com/submit
And it can be less complicated for individuals to stick to their treatment.The fixed mixture drug [http://support.myyna.com/363266/2011-155-eight-520-1059-0003-4819-201110180-00008-naylor-aiken Ern Med. 2011; 155(eight):520?. doi:10.1059/0003-4819-155-8-201110180-00008. Naylor MD, Aiken] method is central to WHO's purpose of delivering antiretroviral drugs to some 3 million individuals with HIV/AIDS in poor countries by 2005, but so far it has been unclear how such massive [https://dx.doi.org/10.3389/fnint.2013.00038 title= fnint.2013.00038] supplies of these drugs will be financed.

Primarily based sexual well being interventions to stop STI/HIV in sub-Saharan Africa.

2018-03-07T08:11:16Z

Quit07rat:

2004 Jan ten; 328(7431): 70.doi: 10.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ [https://dx.doi.org/10.1542/peds.2015-0966 title= peds.2015-0966] [http://www.medchemexpress.com/Hesperetin.html purchase Hesperetin] Publishing Group Ltd.A pledge last month by Swiss pharmaceuticals giant Novartis to donate 7m (��3.9m; �?.5m) worth of drugs to 500 000 [http://www.medchemexpress.com/GR79236.html GR79236 cost] patients with tuberculosis in poor nations over the subsequent 5 years has raised hopes that other drug organizations will comply with suit to fight HIV/AIDS and malaria.Under an agreement with the World Wellness Organization on 19 December, Novartis will provide drugs to help poor countries get and distribute drugs to individuals with tuberculosis. BMC Public Health 2008, 8(4):1?3.doi:ten.1186/1471-2458-14-54 Cite this short article as: Aar?et al.: Promoting sexual and reproductive well being among adolescents in southern and eastern Africa (PREPARE): project style and conceptual framework.Based sexual well being interventions to stop STI/HIV in sub-Saharan Africa. BMC Public Well being 2008, eight(four):1?three.doi:10.1186/1471-2458-14-54 Cite this short article as: Aar?et al.: Advertising sexual and reproductive wellness among adolescents in southern and eastern Africa (PREPARE): project design and conceptual framework. BMC Public Well being 2014 14:54.Submit your subsequent manuscript to BioMed Central and take full advantage of:?Convenient on the internet submission ?Thorough peer overview ?No space constraints or colour figure charges ?Instant publication on acceptance ?Inclusion in PubMed, CAS, Scopus [https://dx.doi.org/10.1007/s40037-015-0222-8 title= s40037-015-0222-8] and Google Scholar ?Research which is freely readily available for redistributionSubmit your manuscript at www.biomedcentral.com/submit
BMJ. 2004 Jan ten; 328(7431): 70.doi: 10.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ [https://dx.doi.org/10.1542/peds.2015-0966 title= peds.2015-0966] Publishing Group Ltd.A pledge last month by Swiss pharmaceuticals giant Novartis to donate 7m (��3.9m; �?.5m) worth of drugs to 500 000 sufferers with tuberculosis in poor countries over the following five years has raised hopes that other drug providers will follow suit to fight HIV/AIDS and malaria.Under an agreement with the World Wellness Organization on 19 December, Novartis will present drugs to assist poor countries get and distribute drugs to sufferers with tuberculosis. Two million people die of the disease every year, several of whom have HIV infection or AIDS. You will discover indicators that the tuberculosis epidemic is expanding.Apart from discounting of patented drugs (such as antiretrovirals for HIV/AIDS) as well as a current trade waiver to allow businesses creating generic drugs to manufacture copies of patented drugs, that is the first time that a significant drug corporation has made a sizable monetary donation.Instead of procuring vast quantities of drugs, which demand sorting, Novartis is manufacturing ready produced "patient kits" for the duration of patients' six month remedy course. The very first packs are as a consequence of be delivered this spring in several countries��expected to include the Philippines, Tanzania, Algeria, Syria, and Turkmenistan.The packs contain blister packs of 28 daily doses. As opposed to taking four separate pills per day, individuals take a single pill containing 4 distinctive drugs for two months along with a single pill containing two drugs for four months.This really is anticipated to keep counterfeit drugs out of your chain and lessen the burden on healthcare workers, who will now only need to have to provide patients access to their every day dose and make a note that they've taken it.